Literature DB >> 10878734

Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus.

S M Weiner1, A Otte, M Schumacher, I Brink, F D Juengling, T Sobanksi, E U Nitzsche, H H Peter.   

Abstract

Neuropsychiatric systemic lupus erythematosus (SLE) is frequently associated with deficits in brain glucose metabolism, even if morphological imaging by magnetic resonance imaging (MRI) shows no abnormalities. In these patients it is unclear whether or not the changes of brain metabolism measured by F-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) may progress to lesions of cerebral structure. We describe a 20-year-old woman with SLE who presented with depression, headache and impairment of memory. Initially, a cranial MRI was negative, but FDG-PET revealed significant hypometabolism in the frontal and parieto-temporo-occipital regions on both sides as well as hypermetabolism in the nuclei caudati. Within two months the patient developed an acute confusional state, seizures, visual disturbances and cranial MRI became positive showing hyperintensities at the basal ganglia and the temporo-occipital regions. Focal cerebral symptoms responded to treatment with high dose corticosteroids and brain lesions in MRI disappeared. However, a second FDG-PET showed persistent hypometabolism at frontal regions in accordance with the persistence of subclinical depression. To our knowledge, this is the first SLE case report showing that functional brain lesions visualized by FDG-PET may be a risk factor for subsequent structural brain damage seen in MRI. Thus, FDG-PET may help to verify cerebral involvement of SLE earlier than MRI.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878734     DOI: 10.1191/096120300678828370

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

Review 1.  Neuropsychiatric lupus.

Authors:  J G Hanly
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

2.  18FDG imaging of giant cell arteritis: usefulness of whole-body plus brain PET.

Authors:  Tarik Belhocine
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-29       Impact factor: 9.236

3.  A plea for the elective inclusion of the brain in routine whole-body FDG PET.

Authors:  Tarik Belhocine; Stefan Markus Weiner; Ingo Brink; Peter Paul De Deyn; Jan Roland; Thierry Van der Borght; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

4.  Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease.

Authors:  Frank Leypoldt; Ralph Buchert; Ingo Kleiter; Jörg Marienhagen; Mathias Gelderblom; Tim Magnus; Josep Dalmau; Christian Gerloff; Jan Lewerenz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-05-07       Impact factor: 10.154

5.  Neuropsychiatric systemic lupus erythematosus.

Authors:  Alexandra Popescu; Amy H Kao
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

6.  Altered Brain Glucose Consumption in Cogan's Syndrome.

Authors:  Paolo Mora; Livia Ruffini; Caterina Ghetti; Stella Ghirardini; Maura Scarlattei; Giorgio Baldari; Carla Cidda; Pierangela Rubino; Stefano A Gandolfi; Jelka G Orsoni
Journal:  J Ophthalmol       Date:  2016-12-06       Impact factor: 1.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.